Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cystic fibrosis transmembrane conductance regulator pseudogene 3 (CFTRP3) is a genomic DNA sequence that is highly homologous to portions of the protein-coding *CFTR* gene but contains disabling mutations (such as frameshifts, truncations, or lack of regulatory elements) that prevent it from producing a functional protein. CFTRP3 is thus classified as a **pseudogene**; it does not contribute to the chloride channel or transporter activity characteristic of the canonical CFTR protein, nor is it involved in cystic fibrosis or any other disease. Its sequence is used in genomic analysis and evolutionary studies but does not have clinical, pharmacological, or diagnostic utility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cystic fibrosis transmembrane conductance regulator pseudogene 3 (CFTRP3).